TAA-CTLs

TAA-CTLs are autologous or allogeneic cytotoxic T lymphocytes engineered or expanded ex vivo to recognize and target **tumor-associated antigens (TAA)** expressed on cancer cells. They are a form of adoptive cell therapy aiming to induce or enhance an antitumor immune response by specifically recognizing TAAs such as NY-ESO-1, MAGEA4, PRAME, Survivin, SSX, Wilms tumor gene 1 (WT1), and others. Upon infusion into patients, the T cells seek out and destroy cancer cells displaying the target antigens, sparing most normal tissues because of limited TAA expression on non-tumor cells. TAA-CTLs have been administered intravenously and are primarily in early-phase clinical trials for relapsed or refractory solid tumors, acute myeloid leukemia (AML), and multiple myeloma. Initial studies show promising safety, disease stabilization, and antitumor effects, especially in patients with minimal residual disease[1][2][3][4][8].

Other names

tumor-associated antigen-specific cytotoxic T lymphocytesTAA-specific CTLsTAA-Ts